|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
14
|
|
pubmed:dateCreated |
1995-8-10
|
|
pubmed:abstractText |
We have investigated the mitogenic effect of three mutant forms of human insulin on insulin-producing beta cells of the developing pancreas. We examined transgenic embryonic and adult mice expressing (i) human [AspB10]-proinsulin/insulin ([AspB10]ProIN/IN), produced by replacement of histidine by aspartic acid at position 10 of the B chain and characterized by an increased affinity for the insulin receptor; (ii) human [LeuA3]insulin, produced by the substitution of leucine for valine in position 3 of the A chain, which exhibits decreased receptor binding affinity; and (iii) human [LeuA3, AspB10]insulin "double" mutation. During development, beta cells of AspB10 embryos were twice as abundant and had a 3 times higher rate of proliferation compared with beta cells of littermate controls. The mitogenic effect of [AspB10]ProIN/IN was specific for embryonic beta cells because the rate of proliferation of beta cells of adults and of glucagon (alpha) cells and adrenal chromaffin cells of embryos was similar in AspB10 mice and controls. In contrast to AspB10 embryos, the number of beta cells in the LeuA3 and "double" mutant lines was similar to the number in controls. These findings indicate that the [AspB10]ProIN/IN analog increased the rate of fetal beta-cell proliferation. The mechanism or mechanisms that mediate this mitogenic effect remain to be determined.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/7603977-1713869,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7603977-1769434,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7603977-1963405,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7603977-2172801,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7603977-2387246,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7603977-2551043,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7603977-2657740,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7603977-2674692,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7603977-2829358,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7603977-3057496,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7603977-3197646,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7603977-3282675,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7603977-3301864,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7603977-3306677,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7603977-3360216,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7603977-3449366,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7603977-3511099,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7603977-3537011,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7603977-3771541,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7603977-3902543,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7603977-6096045,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7603977-6376081,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7603977-6995478,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7603977-7516864,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7603977-7867492,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7603977-7903631,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7603977-8402901,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7603977-8402902
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0027-8424
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
3
|
|
pubmed:volume |
92
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
6239-43
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:7603977-Amino Acid Sequence,
pubmed-meshheading:7603977-Animals,
pubmed-meshheading:7603977-Aspartic Acid,
pubmed-meshheading:7603977-Cell Division,
pubmed-meshheading:7603977-Embryo, Mammalian,
pubmed-meshheading:7603977-Embryonic and Fetal Development,
pubmed-meshheading:7603977-Gestational Age,
pubmed-meshheading:7603977-Humans,
pubmed-meshheading:7603977-Immune Sera,
pubmed-meshheading:7603977-Immunoenzyme Techniques,
pubmed-meshheading:7603977-Insulin,
pubmed-meshheading:7603977-Islets of Langerhans,
pubmed-meshheading:7603977-Leucine,
pubmed-meshheading:7603977-Mice,
pubmed-meshheading:7603977-Mice, Transgenic,
pubmed-meshheading:7603977-Point Mutation,
pubmed-meshheading:7603977-Proinsulin,
pubmed-meshheading:7603977-Proline
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
A transgene coding for a human insulin analog has a mitogenic effect on murine embryonic beta cells.
|
|
pubmed:affiliation |
Department of Anatomy and Cell Biology, State University of New York, Brooklyn 11203, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
